On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc BMRN.
When asked about Black Stone Minerals LP BSM, he said, "I like this situation."
Don’t forget to check out our premarket coverage here.
"That’s it, one of these personalized oncology companies. Here’s what I say about those. Some of them are going to work, and some are not," Cramer said, when asked about Kura Oncology Inc KURA.
Price Action: Shares of BioMarin Pharmaceutical dropped 0.1% to close at $111.15, while Black Stone Minerals fell 1.5% to settle at $15.71 on Wednesday. Kura Oncology shares gained 4.4% to close at $12.47 during the session.
Now Read This: Investor Optimism Improves Ahead Of Key Inflation Data
Photo via Shutterstock.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.